Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Declines By 76.5%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) saw a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 7,300 shares, adeclineof76.5% from the July 15th total of 31,000 shares. Based on an average daily trading volume, of 88,400 shares, the days-to-cover ratio is currently 0.1 days. Currently,0.1% of the company’s shares are short sold. Currently,0.1% of the company’s shares are short sold. Based on an average daily trading volume, of 88,400 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen started coverage on shares of Bio-Path in a research report on Wednesday, May 21st. They set a “sell” rating on the stock.

Bio-Path Trading Down 5.3%

Shares of NASDAQ BPTH opened at $0.13 on Friday. Bio-Path has a 1 year low of $0.12 and a 1 year high of $3.39. The company’s 50-day moving average is $0.16 and its 200 day moving average is $0.22.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.